Structure-efficacy relationships of immunostimulatory activity of CpG-containing oligodeoxynucleotides on mouse spleen cells

Acta Pharmacologica Sinica

Volumn 28, Issue 10, 2007, Pages 1637-1644

  Du, Hai Yan ^b   Xia, Shao You ^c   Song, Hai Feng ^a   Li, Na ^a   Shang, Ming Mei ^a   Zou, Jia ^a   Wang, Qing Qing ^a   Ou, Lun ^a   Sun, Xiao ^a   Ji, Ai Guo ^b   Tang, Zhong Ming ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CpG; Immunostimulation; Oligodeoxynucleotides; Structure activity relationship

Indexed keywords

ALPHA INTERFERON; CHROMIUM 51; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOSTIMULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 6; OLIGODEOXYNUCLEOTIDE DERIVATIVE; THYMIDINE;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOSTIMULATION; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; SPLEEN CELL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD80; ANTIGENS, CD94; B-LYMPHOCYTES; BASE SEQUENCE; CELL PROLIFERATION; CELLS, CULTURED; CPG ISLANDS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34848882764     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00628.x     Document Type: Article

References (31)

1. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995 374 : 546 9.
2. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002 20 : 709 60.
3. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000 164 : 1617 24.
4. Krieg AM. An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med 1996 128 : 128 33.
5. Walker PS, Scharton-Kersten T, Krieg AM, Love-Homan L, Rowton ED, Udey MC, et al. Immunostimulatory oligodeoxy-nucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci USA 1999 96 : 6970 5.
6. Krieg AM, Yi AK, Hartmann G. Mechanisms and therapeutic applications in DNA vaccines. Trends Microbiol 1999 6 : 23 7.
7. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996 157 : 1840 5.
8. Macfarlane DE, Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol 1998 160 : 1122 31.
9. Zhao Q, Matson S, Herrera CJ, Fisher E, Yu H, Kreig AM. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphos-phonate oligonucleotides. Antisense Res Dev 1993 3 : 53 66.
10. Dalpke AH, Zimmermann S, Albrecht I, Heeg K. Phospho-diester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology 2002 106 : 102 12.
11. Sester DP, Naik S, Beasley SJ, Hume DA, Stacey KJ. Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J Immunol 2000 165 : 4165 73.
12. Lee SW, Song MK, Baek KH, Park Y, Kim JK, Lee CH, et al. Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials. J Immunol 2000 165 : 3631 9.
13. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J Immunol 2001 166 : 2372 7.
14. Kadowaki N, Antonenko S, Liu YJ. Distinct CpG DNA and polyi-nosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c type II dendritic precursor and CD11c+ dendritic cells to produce type I IFN. J Immunol 2001 166 : 2291.
15. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004 34 : 251 62.
16. Bao MS, Zhang Y, Wan M, Dai L, Hu XP, Wu XL, et al. Anti-SARS-CoV immunity induced by a novel CpG oligodeoxy-nucleotide. Clin Immunol 2006 118 : 180 7.
17. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000 164 : 944 53.
18. Rankin R, Pontarollo R, Ioannou X, Krieg AM, Hecker R, Babiuk LA, et al. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev 2001 11 : 333 40.
19. Ashman RF. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol 1998 160 : 5898 906.
20. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001 31 : 2154 63.
21. Vollmer J, Weeratna R, Jurk M, Samulowitz U, McCluskie MJ, Payette P, et al. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology 2004 113 : 212 23.
22. Yu D, Zhu FG, Bhagat L, Wang H, Kandimalla ER, Zhang R, et al. Potent CpG oligodeoxynucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun 2002 297 : 83 90.
23. Zhao Q, Temsamani J, Iadarola PL, Jiang Z, Agrawal S. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol 1996 51 : 173 82.
24. Yu D, Zhao Q, Kandimalla ER, Agrawal S. Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg Med Chem Lett 2000 10 : 2585 8.
25. Kandimalla ER, Bhagat L, Yu D, Cong Y, Tang J, Agrawal S. Conjugation of ligands at the 5′-end of CpG DNA affects immuno-stimulatory activity. Bioconjug Chem 2002 13 : 966 74.
26. Yu D, Kandimalla ER, Bhagat L, Tang JY, Cong Y, Tang J, et al. ′Immunomer′-novel 3′-3′-linked CpG oligodeoxynucleotides as potent immunomodulatory agents. Nucleic Acids Res 2002 30 : 4460 9.
27. Bhagat L, Zhu FG, Yu D, Tang J, Wang H, Kandimalla ER, et al. CpG penta- and hexadeoxyribonucleotides as potent immuno-modulatory agents. Biochem Biophys Res Commun 2003 300 : 853 61.
28. Ballas ZK, Kreig AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 2001 167 : 4878 86.
29. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004 34 : 251 62.
30. Hemmi H, Kaisho T, Takeda K, Akira S. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 2003 170 : 3059 64.
31. Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, Takaoka A, et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005 434 : 1035 40.